CIK 0001661998 · Non-accelerated filer<br>Smaller reporting company
Q32 Bio Inc.
Sign in to watch- Ticker
- QTTB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 473468154
- Phone
- 781-999-0232
- Business address
- 830 WINTER STREET, WALTHAM, MA, 02451
- Former names
- Q32 Bio Inc., Homology Medicines, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $320,396
- in 6 filings
Net −$320,396. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-24 | Kalowski Lee CFO and President | Returned to the company · Stock Option (Right to Buy) | −16,901 | 0 | ||
| 2025-02-24 | Kalowski Lee CFO and President | Grant or award · Stock Option (Right to Buy) | +16,901 | 16,901 | ||
| 2025-02-24 | Kalowski Lee CFO and President | Returned to the company · Stock Option (Right to Buy) | −161,323 | 0 | ||
| 2025-02-24 | Kalowski Lee CFO and President | Grant or award · Stock Option (Right to Buy) | +161,323 | 161,323 | ||
| 2025-02-24 | LAPORTE KATHLEEN Director | Returned to the company · Stock Option (Right to Buy) | −5,431 | 0 | ||
| 2025-02-24 | LAPORTE KATHLEEN Director | Grant or award · Stock Option (Right to Buy) | +5,431 | 5,431 | ||
| 2025-02-24 | LAPORTE KATHLEEN Director | Returned to the company · Stock Option (Right to Buy) | −1,947 | 0 | ||
| 2025-02-24 | LAPORTE KATHLEEN Director | Grant or award · Stock Option (Right to Buy) | +1,947 | 1,947 | ||
| 2025-02-24 | LAPORTE KATHLEEN Director | Returned to the company · Stock Option (Right to Buy) | −12,767 | 0 | ||
| 2025-02-24 | LAPORTE KATHLEEN Director | Grant or award · Stock Option (Right to Buy) | +12,767 | 12,767 | ||
| 2025-02-24 | TZIANABOS ARTHUR Director | Returned to the company · Stock Option (Right to Buy) | −25,674 | 0 | ||
| 2025-02-24 | TZIANABOS ARTHUR Director | Grant or award · Stock Option (Right to Buy) | +25,674 | 25,674 | ||
| 2025-02-24 | TZIANABOS ARTHUR Director | Returned to the company · Stock Option (Right to Buy) | −12,767 | 0 | ||
| 2025-02-24 | TZIANABOS ARTHUR Director | Grant or award · Stock Option (Right to Buy) | +12,767 | 12,767 | ||
| 2025-02-24 | Morrison Jodie Pope CEO | Grant or award | +132,000 | 132,000 | ||
| 2025-02-24 | Morrison Jodie Pope CEO | Returned to the company · Stock Option (Right to Buy) | −152,700 | 0 | ||
| 2025-02-24 | Morrison Jodie Pope CEO | Grant or award · Stock Option (Right to Buy) | +152,700 | 152,700 | ||
| 2025-02-24 | Morrison Jodie Pope CEO | Returned to the company · Stock Option (Right to Buy) | −152,700 | 0 | ||
| 2025-02-24 | Morrison Jodie Pope CEO | Grant or award · Stock Option (Right to Buy) | +152,700 | 152,700 | ||
| 2025-02-24 | Morrison Jodie Pope CEO | Returned to the company · Stock Option (Right to Buy) | −16,901 | 0 |
Page 4 of 11 · 207 trades